China Biopharmaceutical (01177) is now up more than 5%. As of press release, it has risen 5.37% to HK$3.14, with a turnover of HK$39.03 million.
The Zhitong Finance App learned that China Biopharmaceuticals (01177) is now up more than 5%. As of press release, it has risen 5.37% to HK$3.14, with a turnover of HK$39.03 million.
According to the news, Zhongsheng Pharmaceutical announced that the two innovative drugs “anlotinib hydrochloride capsules” and “TQB2916 (CD40 agonist)” developed by the group's subsidiary Zhengda Tianqing will present five research results at the 2024 American Cancer Association Annual Meeting (“AACR”).
According to reports, anlotinib is a novel oral small-molecule multi-target receptor tyrosine kinase inhibitor (TKI), which can effectively inhibit VEGFR 1-3 kinases. By regulating tumor microenvironment reprogramming, it can inhibit tumor angiogenesis, inhibit tumor growth, and regulate the immune microenvironment. CD40 agonists mainly exert tumor suppression effects by activating antigen-presenting cells (APC) to promote the activation of immune cells.
HSBC previously pointed out that most of the company's negative factors have been reflected in the stock price. Considering the company's low vaccine inventory level, it is estimated that the impact of impairment will be limited, and it remains optimistic about its growth prospects. The bank believes that the growth prospects for Zhongsheng Pharmaceutical are stable. The current price level is 15 times the price-earnings ratio in 2024, which is 19 times lower than the industry average. The valuation is attractive. It maintains a “buy” rating, and reduces the target price from HK$5 to HK$4.6 in response to the latest valuation.